Upsher Smith Company Profile

✉ Email this page to a colleague

UPSHER SMITH has eighty-eight approved drugs.

There are eight US patents protecting UPSHER SMITH drugs.

There are seventeen patent family members on UPSHER SMITH drugs in ten countries and one hundred and thirty-one supplementary protection certificates in fifteen countries.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upsher Smith Labs	FOSINOPRIL SODIUM	fosinopril sodium	TABLET;ORAL	076188-002	Oct 8, 2004		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Upsher Smith Labs	DROXIDOPA	droxidopa	CAPSULE;ORAL	213661-001	Feb 18, 2021		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Upsher Smith	DEXAMETHASONE	dexamethasone	TABLET;ORAL	087533-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Upsher Smith Labs	KLOR-CON	potassium chloride	FOR SOLUTION;ORAL	209662-001	Oct 23, 2017	AA	RX	No	No		⤷ Start Trial				⤷ Start Trial
Upsher Smith Labs	DIVALPROEX SODIUM	divalproex sodium	TABLET, DELAYED RELEASE;ORAL	078182-003	Jul 29, 2008	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005	6,440,392	⤷ Start Trial
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005	RE43580	⤷ Start Trial
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005	RE40812	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Nasal Spray	200 IU/spray	➤ Subscribe	2006-03-29
➤ Subscribe	Extended-release Capsules	25 mg, 50 mg, 100 mg, 150 mg, and 200 mg	➤ Subscribe	2015-12-24

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Canada	2905011	⤷ Start Trial
South Africa	201604587	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2014143380	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2014143380	⤷ Start Trial
South Korea	102072618	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203431	1590018-6	Sweden	⤷ Start Trial	PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
0788511	SPC/GB08/036	United Kingdom	⤷ Start Trial	PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
1666481	17C1031	France	⤷ Start Trial	PRODUCT NAME: TOFACITINIB,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,DONT LE CITRATE DE SODIUM; REGISTRATION NO/DATE: EU/1/17/1178 20170324
2563920	CR 2019 00001	Denmark	⤷ Start Trial	PRODUCT NAME: INOTERSEN AND SALT THEREOF, INCLUDING SODIUM SALTS; REG. NO/DATE: EU/1/18/1296 20180710
1856135	CA 2020 00018	Denmark	⤷ Start Trial	PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.